FMP
Aura Biosciences, Inc.
AURA
NASDAQ
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
7.19 USD
0.13 (1.81%)
About
ceo
Dr. Elisabet de los Pinos Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.aurabiosciences.com
exchange
NASDAQ
Description
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
CIK
0001501796
ISIN
US05153U1079
CUSIP
05153U107
Address
85 Bolton Street
Phone
617 500 8864
Country
US
Employee
88
IPO Date
Oct 29, 2021
Summary
CIK
0001501796
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
05153U107
ISIN
US05153U1079
Country
US
Price
7.19
Beta
0.35
Volume Avg.
184.49k
Market Cap
355.94M
Shares
-
52-Week
5.99-13.5
DCF
0.54
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-3.73
P/B
-
Website
https://www.aurabiosciences.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest AURA News
It looks like there's no news available.
